Biocytogen’s Post

Headline news from #EADV2024 - Psoriasis Extended half-life antibodies represent a promising advancement for the management of immune-mediated inflammatory diseases, including psoriasis. These antibodies utilize known mechanisms of action but are engineered for prolonged circulation, allowing for less frequent while maintaining efficacy. At #EADV2024 it was presented new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19. ORKA-001 has demonstrated a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. This extended half-life may enable dosing intervals of once every six months or potentially even once yearly. Extended half-life antibodies represent a significant advancement in the management of immune-mediated diseases, including psoriasis, offering the potential to greatly enhance patients' quality of life. #psoriasis #ORKA001 #ExtendedHalflifeAntibodies

🚨 𝗔𝗯𝗯𝗩𝗶𝗲 𝗔𝗰𝗾𝘂𝗶𝗿𝗲𝘀 𝗖𝗲𝗹𝘀𝗶𝘂𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝟮𝟱𝟬𝗠 M&A is to boost IBD treatment portfolio with promising anti-TREM1 antibody, CEL383, targeting inflammatory pathways. The key asset acquired is Celsius' lead investigational drug, CEL383, an anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody designed for treating inflammatory bowel disease (IBD). TREM1 is identified as a critical gene driving inflammation in IBD. CEL383 has completed a Phase 1 clinical study, demonstrating its potential as a first-in-class treatment by inhibiting TREM1 signaling and reducing inflammatory mediators. AbbVie plans to advance CEL383's development to benefit more IBD patients by potentially achieving remission. Congrats all! #immunology #biotech #biopharma #IBD

Biologics can be highly effective in the treatment of cancers, autoimmune disorders, and inflammatory conditions, but their long-term use is associated with the generation of anti-drug antibodies. In a fascinating study published in Cell Reports Medicine, scientists report that a glycopolymer conjugation to a highly immunogenic biologic resulted in reduced cellular and humoral immune responses to the biologic. Prophylactic therapy with the glycopolymer-conjugated biologic mitigated anti-drug antibody responses. Based on these exciting results, a single chemical conjugation of current biologics may enable long-term therapeutic solutions. See the comments section for the full citation and a link to the study in PubMed. #medicine #biomedicalresearch #biomedicalscience #meded #immunology #drugdesign #medicalinnovation #biopodia

COYA 301 and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) are showing promise in the fight against inflammatory diseases. Their synergistic anti-inflammatory effects target various cell types, enhancing regulatory T cell function, suppressing pro-inflammatory cells, and promoting anti-inflammatory phenotypes. This multi-targeted approach addresses multiple pathways simultaneously, offering new hope in treating complex immune-based conditions like Alzheimer’s Disease. Coya Therapeutics, Inc. is at the forefront of investigating these combinations to develop innovative therapeutic strategies for severe systemic, neuro-inflammatory, autoimmune, and metabolic conditions. By expanding their pipeline with proprietary combinations, Coya aims to transform the treatment landscape by targeting multiple disease mechanisms. This breakthrough approach not only extends the GLP-1 market beyond traditional uses but also opens doors for strategic partnerships and scientific collaborations. Learn more about Coya Therapeutics' groundbreaking research and the potential of their novel therapeutic approaches: https://lnkd.in/d6THuJkQ #MedicalResearch #InnovativeTherapies #InflammatoryDiseases #HealthcareInnovation Fred Grossman D.O., FAPA Arun Swaminathan Daniel Barvin, MBA Adrian Hepner, MD, PhD Michelle Frazier, Ph.D.

Fab fragments have therapeutic potential in certain applications. By retaining antigen-binding specificity, Fab fragments can be developed into therapeutic agents for diseases such as cancer, autoimmune disorders, or infectious diseases. Their reduced size facilitates tissue penetration and clearance, potentially improving efficacy and reducing side effects. https://lnkd.in/gnC8R5Q9 #FabFragments #PhageDisplayService #CustomAntibodies #BiotechnologyResearch #ImmunotherapyDevelopment #PrecisionMedicine #DrugDevelopment #BiotechInnovation #MedicalResearch #HealthcareScience #CellularTherapeutics #DiseaseTreatment #AntibodyEngineering #InnovativeSolutions #BioPharmaceuticals #ImmunologyAdvancements #Alphalifetech

Interstitial lung diseases (ILDs) represent a diverse group of over 200 chronic lung conditions that are marked by progressive scarring (fibrosis) of lung tissue, posing significant treatment challenges despite advances in medical science. The heterogeneity of ILDs, including idiopathic pulmonary fibrosis (IPF), sarcoidosis, and hypersensitivity pneumonitis, means that each subtype has distinct pathological mechanisms, making a universal treatment approach unfeasible. In many cases, such as IPF, the etiology remains unclear, complicating the development of targeted therapies. Even when a cause is suspected, such as autoimmune disorders or environmental exposures, halting or reversing disease progression can be difficult. Furthermore, the molecular mechanisms driving fibrosis are complex, involving multiple pathways like inflammation, epithelial injury, and abnormal wound healing. #LungHealth #InterstitialLungDisease #Fibrosis #PulmonaryResearch #IPF #RespiratoryCare #MedicalResearch #HealthcareInnovation #Pharmacology #RareDiseases

I was fascinated by the recent Ph. III data for Boehringer's PDE4B inhibitor nerandomilast (BI 1015550) in IPF. It is rare that a new drug shows improvement in IPF which is an incredibly challenging indication. BI's compound met its primary endpoint in the largest IPF trial conducted to date. The full data will be presented in 2025 and BI will submit an NDA for nerandomilast based on these results. The FDA granted the compound a Breakthrough Therapy Designation in 2022 already. In a recently published report, nerandomilast improved lung function and normalized most transcripts deregulated by bleomycin treatment in a rat model of pulmonary fibrosis. Transcriptomic analysis revealed significant overlap with human IPF data, particularly affecting mesenchymal, epithelial, and endothelial cell populations. In vitro studies using human epithelial cells confirmed nerandomilast's ability to inhibit disease-related biomarkers in a concentration-dependent manner. These findings highlight nerandomilast's anti-inflammatory and antifibrotic mechanisms. PDE4 has been explored as a target since the 1970s. It is well-known that pan-PDE4 inhibitors, like roflumilast and apremilast, have dose-limiting GI side effects including nausea and vomiting, but nerandomilast appears to be well-tolerated. Read more about this and other molecules in our Molecules of the Month Article: https://lnkd.in/gdnKkPyM

After Muromonab-CD3 and Daclizumab, this week we will shine the spotlight on another antibody used to prevent kidney transplant rejection: Basiliximab (Simulect), approved in 1998. 🔬 Antibody type: Chimeric IgG1 💊 Brand name: Simulect 🏢 Company: Novartis 🎯 First indication: Prevention of acute kidney transplant rejection Basiliximab was a significant advancement in kidney transplant medicine. This monoclonal antibody targets the IL-2 receptor alpha chain (CD25) on activated T cells. By binding to CD25, Basiliximab inhibits IL-2 mediated T cell proliferation, which is a crucial process in the immune response leading to transplant rejection. Basiliximab's introduction has provided transplant patients with a safer and effective option to protect their new organs. Stay tuned for our next post, where we will explore more groundbreaking FDA-approved antibodies! #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #TransplantMedicine #KidneyTransplant #Biotechnology #MedicalInnovation

New review on the current research into extracellular vesicles as therapeutic agents, drug delivery systems, and disease biomarkers https://lnkd.in/g6WZjiiE

𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞: 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐨𝐧𝐨𝐜𝐥𝐨𝐧𝐚𝐥 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gUbUmrwu Monoclonal antibodies (mAbs) are at the forefront of medical innovation, offering targeted treatments for a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and more. Let's delve into the dynamics of the monoclonal antibodies market to uncover the innovations and opportunities driving advancements in therapeutic interventions and patient care. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system's attack on harmful cells. These targeted therapies have transformed the treatment landscape, providing high specificity and efficacy in managing complex and chronic conditions. #Company Biocon Celltrion Inc Dr. Reddy's Laboratories Hospira 3SBio Inc. Accord Healthcare AET Biotech Allergan Amega Biotech #Type Erythropoietin (EPO) Human Growth Hormone (HGH) Granulocyte- Colony Stimulating Factor (G-CSF) Monoclonal Antibody (mAb) Insulin Interferon (IFN) Others #Application Anti-Cancer Anti-Inflammatory/Autoimmune #MonoclonalAntibodies #BiotechInnovation #HealthcareRevolution #PatientCare #PharmaceuticalAdvancements